NEMO (IKKγ) citrullination in microglia promotes neuroinflammation in the post-ischemic brain Authors: Sang-A Oh, Song-I Seol, Ja-Kyeong Lee, Il-Doo Kim Published: 2026 ABSTRACT AbstractPeptidylarginine deiminase (PAD) catalyzes the post-translational conversion of positively charged arginine residues into neutral citrulline. This modification, known as citrullination, is implicated in various pathological conditions, including those affecting the central nervous system. This study investigated the pro-inflammatory role of PAD in microglia using a middle cerebral artery occlusion (MCAO) animal model of ischemic stroke. Pharmacological inhibition of PAD via BB-Cl-amidine (BBCA; a pan-PAD inhibitor) exerted robust anti-inflammatory and neuroprotective effects in the post-ischemic brain in a broad therapeutic window. A significant accumulation of citrullinated proteins was detected in activated microglia following ischemia, which was suppressed by BBCA. Notably, we demonstrate that citrullination of NEMO (IKKγ), a key regulator that activates the NF-κB signaling pathway, was significantly induced in the post-ischemic brain, facilitating NEMO-IKKα/IKKβ assembly. Importantly, BBCA inhibited NEMO citrullination and disrupted subsequent IKK assembly, highlighting the critical role of PAD in this process. Targeted knockdown experiments using siRNA in BV2 microglial cells revealed that both PAD2 and PAD4 play crucial role in NEMO citrullination and NF-κB-mediated pro-inflammatory response. Furthermore, inhibiting NEMO citrullination with a NEMO-binding domain peptide (NBDp) or co-treatment with NBDp and BBCA, further supports a crucial role for PAD-mediated NEMO citrullination in post-ischemic neuroinflammation. Collectively, these results suggest that PAD2 and PAD4 drive pro-inflammatory processes following cerebral ischemia by upregulating NEMO citrullination and subsequent IKK complex formation.Keywords: PAD4, Inflammation, MCAO, Microglia, NEMO Introduction Peptidylarginine deiminase (PAD) is a post-translational modification enzyme that catalyzes the conversion of positively charged arginine residues within protein substrates to neutral citrulline, a process known as deimination or citrullination [1]. The PAD family comprises five distinct isoforms (PAD1, PAD2, PAD3, PAD4, and PAD6) each exhibiting tissue-restricted expression [1]. Among these, PAD2 and PAD4 are the primary isoforms expressed in immune cells, where their activity has been implicated in regulating immune cell differentiation and their function [[1], [2], [3], [4]]. Notably, PAD4 is recognized as a key mediator of neutrophil extracellular traps formation (NETosis) via histones citrullination [5]. Furthermore, we recently demonstrated that PAD4 inhibition exerts neuroprotective effects in the post-ischemic brain through both NETosis-dependent and -independent mechanisms [6]. The citrullination-mediated loss of positive charges alters the conformation of target proteins through irreversible modification, potentially inducing their unfolding or misfolding. These conformational shifts can compromise protein stability and impair the capacity for protein-protein interactions [7]. Consequently, dysregulated PAD activity and aberrant protein citrullination have been implicated in a broad spectrum of human pathologies, including rheumatoid arthritis (RA) [8,9], multiple sclerosis (MS) [10,11], Alzheimer’s disease (AD) [12], and progression of various cancers [[13], [14], [15]]. For instance, in RA, PAD4-mediated citrullination of antithrombin leads to its inactivation, thereby contributing to disease progression [8]. Furthermore, the release of active PAD isoforms from dying neutrophil into the synovial fluid may drive the generation of extracellular autoantigens [9]. The pivotal role of PAD4 in diverse pathological conditions is further substantiated by evidence demonstrating that PAD4 deficiency or pharmacological inhibition alleviates disease severity across multiple models [8,[16], [17], [18], [19]]. Notably, association of elevated citrullination levels with various cancers has been reported. PAD2 is highly prevalent in multiple tumor tissues, such as breast cancer [13] and multiple myeloma [14], while elevated PAD4 levels have been reported in esophageal squamous cell carcinoma [15] and in patients with lung cancer secondary to tobacco smoking [20], suggesting its functional relevance in tumorigenesis. Specific PAD isotypes are recognized as playing a pivotal role in the pathogenesis of various central nervous system (CNS) disorders. Of the five PAD isoforms, PAD2 and PAD4 are the primary variants localized within the CNS. The expression of PAD2 in astrocytes and oligodendrocytes, along with its involvement in neurodegenerative diseases is well-documented [[10], [11], [12],21]. In contrast, PAD4 is significantly induced in neurons, neutrophils, and microglia under hypoxic conditions [6,22]. For instance, ischemic stroke triggers a marked upregulation of PAD4, leading to the citrullination of numerous proteins throughout the brain, particularly within the cerebral cortex [22]. Studies on neonates with hypoxic-ischemic brain injury revealed elevated levels of citrullinated proteins, including histone H3, in affected brain regions; these levels were significantly attenuated following treatment with PAD inhibitor [19]. Furthermore, we previously demonstrated PAD4 induction in an animal model of stroke, wherein PAD4 expression was observed in diverse cell types in the post-ischemic brain [6]. Importantly, intranasal administration of the BB-Cl-amidine (BBCA, a pan-PAD4 inhibitor) immediately following MCAO significantly reduced infarct volume and improved neurological and functional outcomes [6]. These findings highlight the robust protective efficacy of PAD4 inhibition in ischemic stroke, which was mediated through both NETosis-dependent and-independent mechanisms [6]. Recent evidence indicates that PAD4 regulates the NF-κB pathway. Specifically, in models of ischemic acute kidney injury (AKI), PAD4 directly and selectively citrullinates NF-κB essential modulator (NEMO), also known as IKKγ, which is the regulatory subunit of the IKK complex [23,24]. Citrullination of IKKγ promotes pro-inflammatory NF-κB signaling within renal tubules, thereby exacerbating the severity of AKI [25]. The functional significance of this PAD4-mediated NEMO citrullination was corroborated by studies utilizing PAD4-deficient mice and recombinant PAD4 [23,24]. Based on our previous study demonstrating a marked induction of PAD4 and an accumulation of citrullinated proteins in both neurons and microglia following cerebral ischemia [6], the present study sought to identify the specific target protein citrullinated by PAD in microglia. Using a transient MCAO model, we investigated whether the PAD-mediated NEMO citrullination contributes to the observed anti-inflammatory effects and determined which specific PAD isoform is responsible for this modification. Materials and Methods Surgical procedure of MCAO induction Male Sprague–Dawley rats (7–8 weeks old) were obtained from Orient Bio Inc (Gyeonggi, South Korea) and housed under a 12 h light/dark cycle with ad libitum access to standard food and tap water. All animal experiments were performed in strict accordance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals (NIH, USA, 2013) and the ARRIVE guidelines (http://www.nc3rs.org/ARRIVE, accessed on August 31, 2021). The experimental protocol was reviewed and approved by the INHA University Institutional Animal Care and Use Committee (INHA-IACUC) prior to the commencement of the study (Approval No. INHA210915-782). Middle cerebral artery occlusion (MCAO) was performed as previously described [26]. Briefly, 8-week-old male Sprague–Dawley rats (250–300 g) were initially anesthetized with 5% isoflurane in a gas mixture of 30% oxygen and 70% nitrous oxide delivered via a close-fitting facemask. Anesthesia was maintained with 0.5% isoflurane in the same gas mixture throughout the surgical procedure. A 4−0 nylon monofilament suture (AILEE, Busan, Korea) with a heat-induced tip (approximately 0.3 mm in diameter) was inserted into the internal carotid artery through the external carotid artery bifurcation and advanced 20–22 mm to occlude the right middle cerebral artery for 1 h. Subsequently, the filament was withdrawn to allow reperfusion for up to 96 h. Sham-operated rats underwent identical surgical procedures, with the exception that the MCA was not occluded. Animals were randomly allocated to the following groups: sham (n = 12), MCAO 3 h (n = 4), MCAO 6 h (n = 4), MCAO 12 h (n = 7), MCAO 24 h (n = 11), MCAO 96 h (n = 4), MCAO + BBCA 0h (n = 5), MCAO + BBCA 3 h (n = 11) and MCAO + BBCA 6 h (n = 5). Neonatal Sprague–Dawley rat pups (P0–P2) from 6 dams were used for in vitro study. A total of 66 pups (mean 11 pups per dam) were allocated randomly to experimental groups. Intranasal administration Drugs were administered intranasally, following the protocol described by Kim et al. [27]. Briefly, rats were anesthetized via intramuscular injection of a mixture of ketamine (3.75 mg/100 g body weight) and xylazine hydrochloride (0.5 mg/100 g body weight). Throughout the procedure, the animals were maintained in a supine position at a 90° angle. Drug delivery was performed using a pre-sterilized pipette tip (T-200-Y; Axygen, Union, CA, USA). A total volume of 20 μL of PBS-dissolved compounds, including BB-Cl-amidine (10 μg/kg, BBCA, HY-111347 A; MedChemExpress, Monmouth Junction, NJ, USA), was carefully administered dropwise into each nostril of anesthetized rats. The administration was conducted in a stepwise manner, with 2-min intervals between successive applications until the full dose was delivered. Infarct volume assessment Following euthanasia, whole brains were isolated and coronally sectioned into 2-mm thick slices using a metallic brain matrix (RBM-40000, ASI, Springville, UT, USA). The brain slices were immediately incubated in 2% 2,3,5-triphenyl tetrazolium chloride (TTC) solution at 37 °C for 15 min and subsequently fixed in 4% paraformaldehyde (PFA; FUJIFILM Wako Pure Chemical, Osaka, Japan). Infarcted areas were quantified using the Scion Image software (Scion Corporation, Frederick, MD, USA). To correct for edema and tissue shrinkage, infarct volumes were calculated using the following formula: contralateral hemisphere volume − (ipsilateral hemisphere volume − measured injury volume). The total infarct volume (mm3) was determined by summing infarct areas across consecutive brain sections. Modified neurological severity scores (mNSS) Neurological deficits were evaluated at 24 h post-MCAO using the modified Neurological Severity Score (mNSS). The mNSS assesses motor, sensory, balance, and reflex functions, with total scores ranging from 0 (normal function) to 18 (maximal deficit) [28]. Motor function was assessed using two tests: (1) tail suspension, where forelimb flexion, hindlimb flexion, and head movement (>10° relative to the vertical axis) were each scored on a binary scale (0 = normal, 1 = deficit), yielding a maximum possible score of 3 within 30 s observation period; and (2) assessment of walking ability on a flat surface, scored on a scale of 0–3 (0 = normal walking, 1 = inability to walk straight, 2 = circling toward the paretic side, 3 = falling on the paretic side). Sensory function was evaluated using the placing test and proprioceptive test, each scored 0 or 1. Balance ability was assessed using the beam balance test, with scores ranging from 0 to 6: 0 = maintaining a steady posture, 1 = grasping the side of the beam, 2 = hugging the beam with one limb off, 3 = hugging the beam with two limbs off or rotating around the beam for more than 60 s, 4 = falling off the beam within 20–40 s, 5 = falling off within 20 s, and 6 = making no attempt to balance or cling to the beam. Reflex function was evaluated based on four criteria, each scored 0 or 1 (maximum score of 4): pinna reflex, corneal reflex, startle reflex, and the presence of seizures, myoclonus, or myodystonia. Primary microglia culture All efforts were made to minimize the number of animals used and their suffering. Primary microglial cultures were established as previously described [29]. Briefly, cerebral hemispheres were isolated from 1-day-old postnatal Sprague-Dawley rat pups. The dissociated cells were seeded at a density of 1.2 × 106 cells/mL in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% penicillin-streptomycin (Gibco BRL, Gaithersburg, MD, USA). After 14 days in culture, microglia were detached from the flasks by gentle shaking and then filtered through a cell strainer (BD Falcon, Bedford, MA, USA) to remove contaminating astrocytes. The collected cells were pelleted by centrifugation at 1000×g for 5 min, resuspended in fresh DMEM containing 10% FBS and 1% penicillin-streptomycin, and then plated at a final density of 1 × 105 cells/mL in 6-well plates (Corning Inc., Corning, NY, USA). After 2 h of incubation, the culture medium was replaced with DMEM supplemented with 5% FBS and 500 μM B27 supplement (Gibco BRL, Gaithersburg, MD, USA). Cell cultures and inhibitor treatment The BV2 murine microglial cell line was cultured in DMEM (Sigma) supplemented with 5% heat-inactivated FBS (Hyclone), 20 U/mL penicillin, and 20 mg/mL streptomycin in a 5% CO2 incubator. Cells were stimulated with lipopolysaccharide (100 ng/ml, LPS; derived from Escherichia coli O111:B4; Sigma-Aldrich, St. Louis, MO, USA) at the concentration specified in each experiment. For the inhibitor treatment, the BV2 cells were pretreated with BBCA (5 μM) for 1 h or NBD peptide acetate (5 μM; NBDp, TP1615L; TargetMol Chemicals Inc., Boston, USA) for 3 h and then treated with LPS (100 ng/mL). Nitrite measurements BV2 cells were seeded in 6-well plates at a density of 1 × 105 cells/mL and stimulated with LPS (100 ng/mL) for 24 h. Nitric oxide (NO) production was assessed by measuring nitrite (NO2−) levels in the conditioned medium using the Griess reagent assay. Briefly, 50 μL of culture supernatant was mixed with an equal volume of Griess reagent (0.5% sulfanilamide, 0.05% N-naphthylene-diamine-H-chloride, and 2.5% H3PO4) and incubated at room temperature for 5 min. Absorbance was measured at 550 nm using a microplate reader, and NaNO2 standards were used to determine NO2− concentrations. Small interfering RNA (siRNA) transfection Mouse PAD2-specific siRNA (siPAD2; 5′-GCU GCA UGA AGG AUA AUU ACC UGdTdT-3′ and 5′- AAC AGG UAA UUA UCC UUC AUG CAG CAC-3′), PAD4-specific siRNA (siPAD4; 5′-AUC AAU GAA AUU CUG UCC AAC AAG A-3′ and 5′-UCU UGU UGG ACA GAA UUU CAU UGA UUG-3′), and a nonspecific control siRNA (siCon; 5′-CGU UAA UCG CGU AUA AUA CGC GUA U-3′ and 5′-AUA CGC GUA UUA UAC GCG AUU AAC GAC-3′) were obtained from Integrated DNA Technologies, Inc. (Coralville, IA, USA). For transfection, siPAD2, siPAD4 and siCon (100 pmol each) were separately mixed with Oligofectamine and Opti-MEM (both from Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. The siRNA-Oligofectamine complexes were then added to BV2 cells (1 × 105 cells/mL) and incubated for 24 h. Plasmid transfection and luciferase assay BV2 cells were seeded in 6-well plates at a density of 1 × 105 cells/mL, and all transfection experiments were conducted using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Briefly, cells were cultured in 400 μL of growth medium supplemented with 5% FBS and 1% penicillin-streptomycin for 24 h prior to transfection. The pGL4.32[luc2P/NF-κB-RE/Hygro] plasmid (Promega, Madison, WI, USA; Cat. No. E849A) was mixed with Lipofectamine 3000 according to the manufacturer’s instructions and then added to the BV2 cells. After 4 h of incubation, the medium was replaced with fresh growth medium, and the cells were further incubated for 16 h. Subsequently, the cells were washed with PBS and lysed in 200 μL of Reporter Lysis Buffer (Promega, Madison, WI, USA). Luciferase activity was measured by mixing 20 μL of cell lysate with 100 μL of Luciferase Assay Reagent (Promega, Madison, WI, USA) and analyzed using an LB 9507 luminometer (Berthold, Calmbacher, Germany). Luciferase activity was normalized to total protein levels derived from the co-transfected plasmid. Immunoblotting Cell and brain homogenates were prepared using RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% NP40, 0.25% sodium deoxycholate, 0.5% Triton X-100, 10% glycerol, and Complete Mini Protease Inhibitor Cocktail tablet (Roche Diagnostics, Basel, Switzerland)]. The resulting cell or tissue extracts were then separated on 9–13% SDS-PAGE gels and suqsequently subjected to immunoblotting with the following primary antibodies: anti-NEMO (1:1000, ab178872, Abcam, Cambridge, UK), anti-LaminB1 (1:1000, ab133741, Abcam), anti-PAD4 (1:1000, GTX113945, GeneTex, Irvine, CA, USA), anti-PAD2 (1:1000, ab322197, Abcam), anti-GAPDH (1:10000, 14C10, Cell Signaling Technology, Danvers, MA, USA), anti-p65 (1:1000, D14E12, Cell Signaling Technology), anti-IκB-α (1:1000, L35A5, Cell Signaling Technology), anti-IKKα (1:1000, 61294T, Cell Signaling Technology), anti-IKKβ (1:1000, 8943T, Cell Signaling Technology), anti-F95 (MABN328, Merck Millipore, Burlington, MA, USA), and anti-iNOS (1:1000, ab15323, Abcam). Immunoreactive bands were detected using anti-rabbit horseradish peroxidase (HRP)-conjugated or anti-mouse HRP secondary antibodies (1:4000, Merck Millipore, Burlington, MA, USA), and the chemiluminescent signal was visualized using a chemiluminescence kit (Merck Millipore). Co-immunoprecipitation assay Co-immunoprecipitation was performed using the Catch and Release v2.0 Reversible Immunoprecipitation System (Merck Millipore, Burlington, MA, USA), following the manufacturer’s protocol. Cell or tissue lysates (500 μg of total protein) were immunoprecipitated with 1 μg anti-F95 (Merck Millipore) or anti-NEMO (Abcam). The immunoprecipitates or input protein lysates were heated at 100 °C for 5 min, separated by 10% SDS-PAGE, and then analyzed by immunoblotting. Immunofluorescence staining Brains were fixed by immersion in 4% paraformaldehyde (PFA) solution for 48 h at 4 °C. This was followed by post-fixation in a 30% sucrose solution at 4 °C. The brains were then sectioned coronally at a thickness of 30 μm using a vibratome. For immunostaining, sections were blocked for 1 h at room temperature with a solution containing 5% FBS, 5% horse serum, and 2% albumin in 0.1% Triton X-100. The following primary antibodies were applied at 1:200 dilution: anti-ionized calcium-binding adaptor molecule-1 (Iba1) (orb18542, Biorbyt, Cambridge, UK), and anti-F95 (MABN328, Merck Millipore). After incubation with primary antibodies overnight, the brain sections were washed three times with PBS and then incubated for 1 h at room temperature with the following secondary antibodies, all diluted 1:200: rhodamine-labeled anti-mouse IgG and FITC-labeled anti-goat IgG (Merck Millipore Corporation). Sections were mounted onto slides using VECTASHIELD Antifade Mounting Solution containing DAPI (Vector Laboratories) and examined under a Zeiss LSM 510 META microscope (Carl Zeiss Meditec AG, Jena, Germany). Immunohistochemistry Animals were sacrificed 24 h post-MCAO after euthanization, and their brains were fixed by transcardiac perfusion with 4% paraformaldehyde, followed by post-fixation in the same solution overnight at 4 °C. Subsequently, brains were sectioned coronally at a thickness of 30 μm using a vibratome. Immunostaining was carried out as previously described [26]. Primary antibodies were incubated with the following dilutions: anti-Iba1 (Wako Pure Chemicals, Osaka, Japan) at 1:500 and anti-Mac-2 (Abcam, Cambridge, UK) at 1:250. After washing with PBS containing 0.1% Triton X-100, sections were incubated with anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA) for anti-Mac-2 or anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) for anti-Iba1 in PBS for 1 h at room temperature. Immunoreactivity was then visualized using the HRP/3,3′-diaminobenzidine (DAB) substrate kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s instructions. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) Total RNA was extracted from the infarct regions of rat brain tissues and cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA synthesis was performed using the iScript cDNA Synthesis Kit (Bio-RAD, Hercules, CA, USA) following the manufacturer’s protocol. Quantitative real-time polymerase chain reaction (RT-qPCR) was carried out using TOPreal qPCR 2X PreMIX SYBR Green with low ROX (Enzynomics, Daejeon, Korea), as following the cycling conditions: initial denaturation at 95 °C for 15 min, followed by 55 cycles of denaturation at 95 °C for 10 s and annealing/extension at 55 °C for 15 s. Primer sequences for the target genes are provided (Table 1). All PCR reactions were performed in triplicate, and the average threshold cycle (Ct) values were calculated for each sample. Gene expression levels were normalized to the housekeeping gene GAPDH, and relative gene expression levels were quantified using the Livak (2 − ΔΔCt) method. Table 1Oligonucleotide primers used for qPCR analysis.Table 1GeneOligonucleotide primer sequencesGenBank accession no.IL-1β5′-GGA GAA GCT GTG GCA GCT A -3′5′-GCT GAT GTA CCA GTT GGG GA -3′NM_008361.4TNF-α5′- CAC CAC GCT CTT CTG TCT ACT -3′5′- GTA CTT GGG CAG ATT GAC CTC -3′NM_013693.3iNOS5′- GCA TCC CAA GTA CGA GTG GT -3′5′- CCA TGA TGG TCA CAT TCT GC -3′NM_001313921.1GAPDH5′- TCA TTG ACC TCA ACT ACA TGG -3′5′- CTA AGC AGT TGG TGG TGC AG -3′NM_001411841.1 Oligonucleotide primers used for qPCR analysis. Enzyme-linked immunosorbent assay (ELISA) TNF-α and IL-6 levels in culture media were measured using an ELISA kit (Cusabio, Houston, TX, USA) according to the manufacturer’s instructions. The culture medium were collected and centrifuged at 6000 rpm for 10 min at 4 °C to remove debris. The supernatants were then transferred to clean polypropylene tubes, and their concentrations were determined using the ELISA kit. Statistical analysis Statistical analysis was performed, San Diego, CA, USA using PRISM software 10.4 (GraphPad Software). Data were initially assessed for normality and homogeneity of variance (if applicable). For comparisons involving multiple groups, One-way or Two-way analysis of variance (ANOVA) was conducted, followed by the Newman–Keuls test was used for post-hoc analysis. Data are presented as mean ± SEM and p-values <0.05 was considered statistically significant. Results PAD inhibition exerts anti-inflammatory and neuroprotective effects in the post-ischemic brain with a wide therapeutic window We previously demonstrated the neuroprotective effect of BBCA in the post-ischemic brain when administered immediately following reperfusion (suture removal) [6]. In the present study we investigated whether an anti-inflammatory mechanism underlies these neuroprotective effects. To evaluate the therapeutic window of BBCA, it was administered intranasally (10 μg/kg) at 0, 3 or 6 h post-MCAO (Fig. 1a). BBCA treatment resulted in a time-dependent reduction in mean infarct volume (Fig. 1b and c). Similarly, the mean modified neurological severity scores (mNSS) at 24 h post-MCAO were significantly improved in a time-dependent manner (Fig. 1d), indicating that BBCA exerts robust neuroprotective effects even with delayed administration. To elucidate the anti-inflammatory properties of BBCA, brain sections were collected at 24 h post-MCAO and immunostained for Iba-1 and Mac2 (a marker of activated microglia). In sham-operated controls, Iba-1-positive cells exhibited a typical ramified morphology (Fig. 1e). Following MCAO, these cells transitioned to an amoeboid phenotype of activated microglia, characterized by enlarged cell bodies and retracted branches (Fig. 1f). However, in the BBCA-treated MCAO groups, Iba-1-positive cells largely retained their ramified morphology (Fig. 1g). While Mac2-positive cells were virtually absent in sham controls (Fig. 1h), their numbers significantly increased in saline-treated MCAO brains (Fig. 1i); this induction was markedly attenuated by BBCA treatment (Fig. 1j). Quantitatively, the increased area occupied by Iba-1 and Mac2-positive cells in MCAO controls was significantly reduced in the BBCA groups (Fig. 1k-l). Furthermore, BBCA suppressed the induction of pro-inflammatory markers (iNOS, TNF-α, IL-1β) in the ischemic cortex (Fig. 1m-o). Collectively, these findings demonstrate that BBCA exerts robust anti-inflammatory and neuroprotective effects in the post-ischemic brain with a broad therapeutic window. Neuroprotective and anti-inflammatory effect of BBCA in the post-MCAO brain. (a) BBCA (10 μg/kg) was administered intranasally 0, 3, or 6 h post-MCAO. (b–d) Representative TTC-stained coronal brain sections (b) and quantification of mean infarct volumes (c) at 24 h post-MCAO were presented. Neurological deficits were assessed using the modified neurological severity scores (mNSS) at 24 h post-MCAO (d). Data are presented as the means ± SEM. Sham, sham-operated animals (n = 4); MCAO, saline-treated MCAO control animals (n = 5); MCAO + BBCA, BBCA-administered MCAO animals (n = 5 for each administration time). (E–O) BBCA (10 μg/kg) was administered intranasally 3 h post-MCAO and immunohistochemistry and quantitative PCR (qPCR) were performed at 24 h post-MCAO. (e–j) Coronal brain sections were obtained from sham-operated (e, h), MCAO-induced (f, i), and MCAO + BBCA-treated (g, j) rats at 24 h post-MCAO, and immunostained with antibodies against Iba1 (e–g) or Mac-2 (h–j). Representative images from three independent experiments are shown. The areas of Iba1-positive or Mac-2-positive cells within 0.5 mm2 region were quantified and are presented as means ± SEM (n = 12 from three animals) (k, l). The insets in (e–j) display high-magnification views of the respective images. Scale bars represent 100 μm, and those in the insets represent 50 μm. (m–o) RNA samples were extracted from the indicated region in (a), and pro-inflammatory marker expression levels were determined by RT-qPCR. Data are presented as the means ± SEM (n = 4/group). One-way ANOVA, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to the sham and ##p < 0.01, ###p < 0.001, $$$p < 0.001 between indicated groups. Accumulation of citrullinated proteins in activated microglia within the post-ischemic brain We next investigated whether citrullinated proteins accumulate within microglia following cerebral ischemia. Triple immunofluorescence staining using F95 (an anti-pan-deimination/citrullination antibody), anti-Iba1 antibody, and DAPI revealed basal levels of protein citrullination in microglia of sham-operated controls, with F95 immunoreactivity localized predominantly within the nucleus (arrows, Fig. 2a). At 24 h after MCAO, a marked increase in citrullinated proteins was evident in both the nucleus and cytoplasm (arrows, in Fig. 2b). Consistent with our previous findings [6], F95 immunoreactivity was also observed in Iba1-negative cells (arrowheads, Fig. 2a–c), which were subsequently identified as neurons or astrocytes (Fig. S1). Notably, while citrullinated proteins were present in microglia across both the ischemic penumbra and the core (arrows, Fig. 2b), citrullination in neurons was primarily restricted to the penumbra, with minimal detection in the core (arrowheads, Fig. 2b). Importantly, intranasal administration of BBCA (10 μg/kg) immediately following surgery significantly attenuated F95 immunoreactivity in microglia at 24 h post-MCAO (Fig. 2c and d). Collectively, these results demonstrate that the ischemia-induced accumulation of citrullinated proteins in activated microglia is effectively suppressed by BBCA. Accumulation of citrullinated proteins in microglia in the post-ischemic brain. Coronal brain sections were obtained from sham-operated controls (a), and the penumbra-core boundary region of 24 h post-MCAO-induced group (b) or of MCAO + BBCA-treated group (c). Triple immunofluorescence staining was performed using antibodies against F95 (red) and Iba1 (green), and DAPI (blue). Arrows indicate F95 immunoreactivity in the microglia (Iba1-positive cells), and arrowheads indicate F95 immunoreactivity in non-Iba1-positive cells. (d) Quantification of the ratio of F95-positive cells to Iba1-positive cells (n = 12 from 3 animals). Scale bars represent 50 μm. One-way ANOVA, ∗p < 0.05 compared to the sham group and #p < 0.05 between indicated groups. BBCA-induced PAD inhibition attenuates post-ischemic neuroinflammation by suppressing NEMO citrullination and NF-κB signaling Given the anti-inflammatory effects of BBCA and the accumulation of citrullinated proteins in activated microglia in the post-ischemic brain, we hypothesized that specific citrullinated targets within microglia drive the inflammatory response. We therefore investigated the NEMO (IKKγ) as a potential candidate. While total NEMO protein levels remained stable in the post-ischemic brain (Fig. 3b), a significant increase in citrullinated NEMO was detected in the cortical penumbra as early as 3 h post-MCAO (Fig. 3c). This modification peaked at 12 h (∼6.0 fold) and was sustained through 24 h (Fig. 3c). This enhancement was further confirmed via reciprocal co-immunoprecipitation experiments using F95 and anti-NEMO antibodies (Fig. 3c). To assess the biochemical efficacy of BBCA, we administered the inhibitor at 3 h post-MCAO (Fig. 3a), a time point that confers significant infarct suppression effect in Fig. 1b and c (Fig. 3a). BBCA significantly suppressed ischemia-induced NEMO citrullination at 24 h (Fig. 3d). Input controls using the F95 antibody revealed a broad spectrum of citrullinated proteins across various molecular weights in the post-ischemic brain, the abundance of which was globally reduced by BBCA treatment (Fig. 3d, right panels). Crucially, the interaction between NEMO and IKKα/IKKβ was markedly enhanced at 24 h post-MCAO; however, it was significantly disrupted by BBCA administration (Fig. 3e and f). These data suggest that citrullination of NEMO facilitates its assembly with the IKKα/IKKβ interaction. As expected, BBCA treatment suppressed p65 nuclear translocation and the degradation of cytoplasmic IκBα (Fig. S2). Collectively, these data demonstrate that the suppression of NEMO citrullination by BBCA plays a critical role in suppressing NF-κB activation and subsequent anti-inflammatory effects in the ischemic brain. BBCA attenuates NEMO citrullination and NEMO-IKKα/IKKβ complex formation in the post-ischemic brain. (a) Protein lysates were purified from the cortical penumbra at 3, 6, 12 and 24 h post MCAO. (b) Total NEMO protein levels were assessed by immunoblotting. (c) Levels of citrullinated NEMO were determined by co-immunoprecipitation experiment. Input controls for F95-immunoprecipitation of brain tissue lysates are shown in the right panel. (d–f) BBCA (10 μg/kg) was administered intranasally 3 h post-MCAO (a), and NEMO citrullination was assessed at 24 h post-MCAO (d). Input controls for F95-immunoprecipitation of brain tissue lysates, with or without BBCA administration, are shown in the right panel. (e, f) Co-immunoprecipitation experiments were performed using tissue lysates with anti-NEMO antibody (immunoprecipitated), followed by immunoblotting with antibodies against IKKα or IKKβ. Data are presented as means ± SEMs (n = 4 for each group). One-way ANOVA, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to sham-operated controls and ##p < 0.01, ###p < 0.001, $$p < 0.05 between indicated groups. BBCA-mediated PAD inhibition exerts anti-inflammatory effect in activated microglia by suppressing NEMO citrullination and NEMO-IKKα/IKKβ complex formation To confirm that the BBCA-mediated regulation of NEMO citrullination and NF-κB signaling occurs specifically in microglia, we examined the pro-inflammatory response in primary microglia cultures. Pretreatment with BBCA (5 μM) starting 1 h prior to LPS stimulation effectively suppressed nitrite production at both 12 and 24 h (Fig. 4a). Furthermore, BBCA significantly attenuated the LPS-induced upregulation of the pro-inflammatory markers, iNOS, IL-1β, and TNF-α in primary microglia (Fig. 4b–d). To further evaluate the anti-inflammatory effects of BBCA, we examined the expression of anti-inflammatory markers, TGF-β, CD206, and IL-10 in LPS-stimulated BV2 cells. BBCA treatment significantly increased the expression of these anti-inflammatory and reparative markers compared with LPS stimulation (Fig. S3). We further investigated the mechanism using BV2 microglial cells. Similar to our in vivo observation, NEMO citrullination was significantly elevated within 1 h of LPS treatment, while total NEMO protein levels remained unchanged (Fig. S4). Importantly, BBCA treatment significantly reduced this NEMO citrullination at 3 h time point (Fig. 4e). Interestingly, the input control revealed a broad increase in various citrullinated proteins following LPS stimulation, which was largely abrogated by BBCA (Fig. 4e, right panels). Crucially, co-immunoprecipitation analysis of BV2 cell lysates demonstrated that LPS stimulation enhanced the interaction of NEMO with IKKα or IKKβ; however, these interactions were significantly disrupted by BBCA (Fig. 4f and g). While we cannot entirely rule out a potential effect of BBCA on the total expression levels of IKKα and IKKβ expressions, our findings strongly suggest that NEMO citrullination is essential for the assembly of the IKK complex. To determine whether these molecular events also occur under ischemia-relevant conditions, we subjected BV2 cells to oxygen-glucose deprivation/reperfusion (OGD/R). Consistent with the findings obtained following LPS stimulation, OGD/R significantly increased NEMO citrullination and enhanced the interaction of NEMO with IKKα and IKKβ (Fig. S5). These findings demonstrate that the molecular events observed in the LPS model are also recapitulated under ischemia-relevant conditions. Collectively, these data demonstrate that LPS-induced NEMO citrullination occurs in microglia and plays a crucial role in NF-κB activation. BBCA exhibited anti-inflammatory effect in activated microglia and suppressed NEMO citrullination and NEMO-IKKα/IKKβ complex formation. (a-d) Primary microglia cultures were treated with BBCA (5 μM) starting 1 h prior to LPS stimulation. (a) Nitrite levels were determined by NO assay at 12 and 24 h after LPS stimulation, with or without BBCA treatment. (b–d) Levels of pro-inflammatory marker (TNFα (β), IL-1β (c), and iNOS (d)) were assessed by qPCR at 12 and 24 h after LPS stimulation. Data are presented as the mean ± SEM (n = 4/group). (e) BV2 cells were treated with BBCA (5 μΜ) at 1 h prior to LPS stimulation (100 ng/ml), and NEMO citrullination was determined at 3 h post-LPS stimulation. Input controls for BV2 cell lysates, treated with or without BBCA are shown in the right panels. Additional input control of NEMO using protein sample obtained after IP with anti-NEMO antibody is included in E. (f, g) BV2 cells were treated with BBCA (5 μΜ) at 1 h prior to LPS stimulation (100 ng/ml), and co-immunoprecipitation experiments were performed using cell lysates with anti-NEMO antibody (immunoprecipitated), followed by immunoblotting with antibodies against IKKα or IKKβ. Data are presented as means ± SEMs (n = 4/group). Two-way ANOVA was used for (a–d) and one-way ANOVA for (e–g). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to untreated control and #p < 0.05, ##p < 0.01, ###p < 0.001, $$$p < 0.001 between indicated groups. Both PAD2 and PAD4 contribute to the inflammatory response in LPS-stimulated microglia Since BBCA acts as a pan-PAD inhibitor, we sought to delineate the individual contributions of PAD2 and PAD4 to the observed anti-inflammatory effects using siRNA-mediated gene knockdown. BV2 cells were transfected with specific siRNAs targeting PAD2, PAD4, or scrambled control siRNA, 24 h prior to LPS treatment (Fig. 5a). The successful reduction of PAD2 and PAD4 levels in both normal and LPS-stimulated cells was confirmed (Fig. S6). The increases in NO production and TNFα, IL-1β, and iNOS expression observed at 24 h post-LPS treatment was significantly suppressed in PAD2-knockdown group compared to the scrambled control (Fig. 5b–e). Interestingly, a comparable or more pronounced suppressive effect was observed in PAD4-knockdown group (Fig. 5b–e), suggesting that both isoforms are involved in the pro-inflammatory process. To further validate the roles of PAD2 and PAD4 in regulating NF-κB signaling, we performed a luciferase reporter assay using Luc2p/NF-κB-RE construct containing five copies of NF-kB binding site (Fig. 5f). The increased luciferase activity in LPS-stimulated microglia (6.5-fold) was significantly attenuated in both the PAD2-and PAD4-knockdown groups but not in the scrambled siRNA control group (Fig. 5f). Collectively, these findings demonstrate that the anti-inflammatory effects of BBCA in LPS-stimulated microglia is likely mediated by the inhibition of PAD2 and PAD4, both of which modulate NF-κB signaling pathway. Anti-inflammatory effects of PAD2 and PAD4 knockdown in LPS-stimulated microglia. (a) BV2 cells were transfected with siRNA for PAD2 (siPAD2), PAD4 (siPAD4), or scrambled control (sc-si) 24 h prior to LPS stimulation (100 ng/ml). (b) Nitrite levels were determined by NO assay at 24 h after LPS stimulation, with or without BBCA treatment. (c–e) Levels of pro-inflammatory marker (TNFα (c), IL-1β (d), and iNOS (e)) were assessed by ELISA at 12 h after LPS stimulation. (f) BV2 cells were transfected with NFκB-Luc reporter plasmid 24 h prior to assay, and LPS (100 ng/ml)-induced NF-κB activity was measured with or without transfecting PAD2 or PAD4 siRNA 24 h prior to LPS stimulation (100 ng/ml) as shown in (a). Luciferase activity and all other data are presented as means ± SEMs (n = 4/group). One-way ANOVA, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to untreated group. #p < 0.05, ##p < 0.01, ###p < 0.001, $p < 0.05 between indicated groups. Both PAD2 and PAD4 are essential for NEMO citrullination and subsequent NF-kB activation in LPS-stimulated microglia Next, we investigated whether the suppression of NEMO citrullination serves as the molecular mechanism underlying anti-inflammatory effects observed in PAD2-and PAD4-knockdown BV2 cells (Fig. 5). NEMO citrullination observed at 3 h post-LPS treatment was significantly reduced in BV2 cells transfected with either PAD2-or PAD4-targeted siRNA, whereas no such reduction was seen in the scrambled control group (Fig. 6a). These results indicate that both PAD2 and PAD4 play non-redundant roles in the citrullination of NEMO within activated microglia. Furthermore, the ischemia-induced recruitment of IKKα and IKKβ to NEMO, which was previously shown to increase at 3 h post-LPS (Fig. 4f and g), was significantly abrogated by the knockdown of either PAD2 or PAD4 (Fig. 6b and c). Collectively, these results demonstrate that both PAD2 and PAD4 facilitate NEMO citrullination, which is a prerequisite for the assembly of the IKK complex and subsequent activation of NF-κB signaling in microglia. Both PAD2 and PAD4 play a role in NEMO citrullination and subsequent activation of NF-kB signaling in LPS-stimulated microglia. BV2 cells were transfected with PAD2 (siPAD2) or PAD4 siRNA (siPAD4) or scrambled control siRNA (sc-si) 24 h prior to LPS stimulation (100 ng/ml). (a) NEMO citrullination was assessed at 3 h post-LPS stimulation. Input controls for BV2 cell lysates transfected with or without PAD2 or PAD4 siRNA are shown in the right panels. Additional input control of NEMO using protein sample obtained after IP with anti-NEMO antibody is included. (b, c) Co-immunoprecipitation experiments were performed using cell lysates with anti-NEMO antibody (immunoprecipitated), followed by immunoblotting with antibodies against IKKα (b) or IKKβ (c). Data are presented as means ± SEMs (n = 4/group). One-way ANOVA, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to controls and #p < 0.05, ##p < 0.01, ###p < 0.001 between indicated groups. NEMO represents a common molecular target for the anti-inflammatory effects of BBCA and the NEMO-binding domain peptide (NBDp) To further validate PAD-mediated NEMO citrullination, we examined the suppressive effects of BBCA on NEMO citrullination in the presence of the NEMO-binding domain (NBD) peptide (NBDp). NBDp is an 11-amino-acid peptide derived from the C-terminal of NBD in IKKβ [[30], [31], [32]]. As a highly specific NF-κB inhibitor, NBDp disrupts the association between NEMO and IKKα/IKKβ, thereby preventing the assembly of the functional IκB kinase (IKK) complex [[30], [31], [32]]. We recently demonstrated that NBDp confers robust neuroprotection in the post-ischemic brain [33], an effect potentially stemming from its ability to inhibit NEMO-IKKα/IKKβ complex formation in microglia [33]. We hypothesized that BBCA and NBDp might converge on NEMO as a common molecular substrate. Notably, NBDp treatment alone significantly attenuated NEMO citrullination (Fig. 7b), suggesting that the binding of NBDp to NEMO effectively masks or blocks the sites required for citrullination. Furthermore, when BBCA was administered to LPS-stimulated cells already pretreated with NBDp (Fig. 7a), we observed no additive reduction in NEMO citrullination compared to BBCA treatment alone (Fig. 7b). This lack of synergism suggests that both agents act via the same molecular target. While the inhibition the NEMO-IKKα/IKKβ interaction by the combined treatment of NBDp and BBCA was comparable to single treatment with NBDp (Fig. 7c and d), the same combined treatment led to a further significant reduction in the induction of proinflammatory cytokines (Fig. 7e–g). These findings were corroborated by ELISA analysis of secreted cytokines in the culture media (Fig. 7h and i). Collectively these results suggest that while BBCA-mediated PAD inhibition alleviates inflammation by preventing NEMO citrullination, it also likely engages additional regulatory mechanisms, thereby exerting a potent, multi-faceted anti-inflammatory effect in activated microglia. Suppression of NEMO citrullination by NBDp and NBDp plus BBCA treatment in LPS-stimulated microglia. (a) BV2 cells were pre-treated with NBDp (5 μM) starting 3 h prior to LPS and then treated with BBCA (5 μM) starting 1 h prior to LPS (100 ng/ml) stimulation. (b) Levels of citrullinated NEMO were determined by co-immunoprecipitation experiment at 3 h after LPS stimulation. Input controls for NEMO-immunoprecipitation of brain tissue lysates, with or without NBDp and BBCA administration, are shown in the right panel. (c, d) Co-immunoprecipitation experiments were performed using tissue lysates obtained from ischemic hemisphere at 3 h after LPS treatment with anti-NEMO antibody (immunoprecipitated), followed by immunoblotting with antibodies against IKKα or IKKβ. Input controls for NEMO-immunoprecipitation of cell lysates, with or without NBDp and BBCA administration, are shown in the right panel. (e–g) Levels of proinflammatory marker (TNFα, IL-1β, and iNOS) expression were assessed by qPCR at 12 h after LPS stimulation. (h, i) Levels of proinflammatory marker (TNFα, IL-6) expression were assessed by ELISA at 12 h after LPS stimulation. Data are presented as the mean ± SEM (n = 4/group). One-way ANOVA, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to controls, #p < 0.05, ##p < 0.01, ###p < 0.001 compared to LPS-treated controls, and $p < 0.05, $$p < 0.01, &p < 0.05, &&p < 0.01, &&&p < 0.001 between indicated groups. Discussion This study demonstrates that NEMO citrullination plays a critical role in the pro-inflammatory response in activated microglia following cerebral ischemia. We found that NEMO citrullination persists for at least 24 h in the post-ischemic brain, and that pharmacological inhibition of this modification via BBCA significantly disrupts the NEMO-IKKα/IKKβ interaction, thereby exerting a potent anti-inflammatory effect. NEMO contains thirty-one arginine residues. The minimal binding domain required for IKKβ recognition has been mapped to amino acid residues 44–111 [34], a region containing eight arginine residues. Notably, structural studies have identified R62, R75, and R101 within three distinct interaction pockets of the NEMO IKKβ-binding domain [35,36]. Given that citrullination neutralizes the positive charge of arginine residues, modification of these or other structurally relevant arginine residues could potentially alter NEMO–IKK interactions. However, the specific NEMO residues targeted for citrullination remain to be identified. Notably, this sustained inflammatory signaling (NEMO citrullination) likely explains the extended therapeutic window of BBCA in MCAO-induced stroke (Fig. 1b–d). The pro-inflammatory role of PAD4-mediated NEMO citrullination is consistent with findings in renal proximal tubular cells during ischemic acute kidney injury [23,24] and in human trophoblast cell invasion and migration [37]. Beyond NEMO, other components of the NF-κB pathway may be regulated by citrullination. For instance, citrullination of NF-κB p65 has been reported to enhance its nuclear localization in neutrophils and subsequent IL-1β and TNFα expression [38]. Additionally, a recent report showed PAD2-mediated p65 citrullination modulates macrophage polarization in acute lung injury [39]. Although, we observed that p65 citrullination levels were comparatively low in activated microglia (Fig. S7), BBCA-mediated suppression of this modification suggests it may still contribute to the microglial inflammatory cascade. Further studies utilizing isoform-specific PAD inhibitors are warranted to further delineate the relative contributions of p65 citrullination and to identify the specific PAD isoform responsible for this modification in the CNS. In the present study, we demonstrated that both PAD2 and PAD4 are involved in NEMO citrullination in activated microglia, with knockdown of either isoform significantly attenuating pro-inflammatory cytokine induction and NF-κB signaling (Fig. 5c–f). Interestingly, both PAD2 and PAD4 were constitutively expressed under basal conditions and were significantly upregulated following LPS stimulation, although their induction profiles differed (Fig. S8). These findings further support the involvement of both PAD2 and PAD4 in the pro-inflammatory response of activated microglia. To further validate these findings in vivo, we examined the expression patterns of PAD4 in post-ischemic brain tissue via immunofluorescence staining. We observed a robust increase in PAD4 immunoreactivity within Iba1-positive microglia in the penumbra. These in vivo observations corroborate our in vitro data. Nevertheless, further investigation utilizing isoform-specific inhibitors is necessary to fully delineate the distinct pathological roles of PAD4 in vivo (Figs. S9 and S10). The implications of PAD2-or PAD4-mediated citrullination in pro-inflammatory processes independent of NF-κB signaling have been documented in various pathological conditions. For example, PAD4-generated citrullinated proteins and their proteolytic fragments can act as neoantigens that trigger autoantibody production in rheumatoid arthritis (RA) [[40], [41], [42]]. Similar autoimmune-like responses have been implicated in several neurodegenerative diseases [43,44]. Additionally, dysregulated PAD2 or PAD4 activity is linked to the pathogenesis of diabetes [45], alopecia areata [46], and systemic lupus erythematosus [47]. While ischemic stroke is primarily characterized by acute neuronal injury driven by excitotoxicity and oxidative stress, it also lead to progressive necrotic neuronal death, resulting in the release of intracellular components. It is plausible that citrullinated proteins and their degradation products are among these released DAMPs, thereby eliciting immune responses. Our co-immunoprecipitation experiments support this possibility; F95 immunoblotting of lysates revealed a broad spectrum of citrullinated proteins with varying molecular weight in both LPS-stimulated microglia (Fig. 4e) and in the post-ischemic brain tissue (Fig. 3c). These proteins represent potential candidates for modification-driven pro-inflammation inducers. Consequently, further investigations to identify these additional substrates and elucidate their roles in stroke pathology are warranted. NBDp is a cell-permeable peptide spanning the NBD of IKKα and IKKβ [[30], [31], [32]]. Our study revealed that NBDp suppresses NEMO citrullination, suggesting a potential structural overlap or biochemical interference between the NBDp-NEMO interaction site and the BBCA target sequence within NEMO. Although we recently reported the robust neuroprotective efficacy of NBDp in the post-ischemic brain [33], present study is the first to demonstrate that the anti-inflammatory mechanism of NBDp is, at least partially, attributable to its inhibition of NEMO citrullination. Notably, while NBDp effectively disrupts NEMO-IKKα/IKKβ complex assembly and suppresses proinflammatory cytokine upregulation, co-treatment of NBDp and BBCA resulted in a further suppression of pro-inflammatory cytokine induction. This observation suggests that BBCA exerts broader inhibitory effects by targeting a wider array of substrates beyond NEMO, thereby further mitigating pro-inflammatory processes. Moreover, a recent report indicates that BBCA inhibits the activation of the stimulator of interferon genes (STING) in bone marrow-derived macrophages, potentially offering an additional anti-inflammatory pathway exerting by BBCA [48]. Therefore, multiple molecular mechanisms beyond the inhibition of NEMO citrullination likely contribute to the anti-inflammatory effects of BBCA, warranting more comprehensive investigation. Given the calcium-dependent nature of PAD4 activity [49,50], its functional induction in activated microglia requires a significant rise in intracellular calcium levels. Microglial calcium dynamics are tightly regulated, with cytosolic calcium fluctuations serving as key indicators of cellular activation [51]. We observed a rapid increase in intracellular calcium levels in BV2 cells following LPS stimulation (Fig. S11). Similarly, in the post-ischemic brain, substantial local ATP accumulation occurs via multiple pathways [[52], [53], [54]], contributing to various detrimental outcomes on brain cells, including the induction of NETosis, as previously reported [55]. As the P2X7 receptor, ATP-activated cation channel, is predominantly expressed on microglia in the CNS [56,57], it is plausible that ATP/P2X7-mediated calcium influx serves as a primary driver of PAD activation in microglia in the post-ischemic brain. Further investigation into the intricate interplay between microglial calcium dynamics, particularly via the ATP/P2X7-mediated one, and the specific regulation of PAD2 and PAD4 isoforms is essential to fully understand this neuroinflammatory mechanism. Despite these findings, several aspects of the present study warrant further consideration. First, although our in vitro findings demonstrate the involvement of both PAD2 and PAD4 in NEMO citrullination, the use of a pan-PAD inhibitor in vivo does not allow the relative contribution of each PAD isoform to be determined. Moreover, the mechanisms underlying the differential regulation of PAD2 and PAD4 during microglial activation remain unclear. Their distinct induction profiles following LPS stimulation (Fig. S8) suggest that isoform-specific regulatory properties may influence their relative contributions to NEMO citrullination and downstream inflammatory signaling. Second, the present study did not distinguish resident microglia from infiltrating monocyte-derived macrophages or examine the potential contribution of other peripheral immune cell populations. These populations may exhibit distinct patterns of PAD expression and NEMO citrullination and contribute differently to post-ischemic inflammatory responses. Finally, the present study primarily focused on the acute phase of ischemic stroke and did not evaluate long-term neurological and functional outcomes. In conclusion, our study demonstrates that NEMO citrullination represents an important molecular mechanism linking PAD activity to NF-κB-mediated neuroinflammation following ischemic stroke. PAD2/PAD4-mediated citrullination of NEMO facilitates IKK complex assembly and subsequent NF-κB activation, thereby promoting pro-inflammatory responses in microglia. Pharmacological inhibition of PAD activity disrupts this signaling process and alleviates post-ischemic inflammation and brain injury. These findings expand our understanding of the role of protein citrullination in neuroinflammation and establish NEMO citrullination as a functional regulatory mechanism of inflammatory signaling in the post-ischemic brain. Ethics approval and consent to participate Not applicable. Authors’ contributions J.L. and S.O. conceived and designed the study; J.L., I.K., and S.S. developed the methodology, wrote and revised the manuscript; S.O., S.S., I.K., and J.L. acquired, interpreted, and analyzed the data; and S.S. provided technical and material support. All the authors have read and approved the final manuscript. Availability of data and materials The data sets generated during the current study are available from the corresponding author on reasonable request. Funding This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1A2C2010920 to J.-K.L. and RS-2025-00523634 to I.-D.K). Conflicts of interest The authors declare no conflicts of interest. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.neurot.2026.e01082. Contributor Information Ja-Kyeong Lee, Email: jklee@inha.ac.kr. Il-Doo Kim, Email: idkim@inha.ac.kr. Supplementary data The following is the Supplementary data to this article. Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement The data sets generated during the current study are available from the corresponding author on reasonable request.